| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ebfd716a6d868cec0fdcf2af2480107 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
1995-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41cd9c13076a598757396f712ce7e6a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53a1b413488657d01a9e05076a3519a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b63822648669013071d6f5c3bd43d4bd |
| publicationDate |
2003-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1369487-A2 |
| titleOfInvention |
Recombinant vectors derived from adenovirus for use in gene therapy |
| abstract |
The invention provides novel vectors derived fromnadenovirus which are specifically suitable for use in methodsnof gene therapy. n The vectors have a deletion compared to wild-typenadenovirus in that the E1 region is not present in anfunctional manner. n Additionally the vectors are characterized in that theyndo contain a part of the E3 region of adenovirus which isnbiologically functional. This results in vectors which donnormally not lead to expression of adenoviral proteins, butnwhich in the cases where such proteins do become expressednwill repress the host's immunological response to saidnproteins. Thereby host cells infected (provided) with thenvector will live longer. Therefor the product introduced intonsaid cells providing the therapy will be produced in largernamounts, or at least for a prolonged period. Preferably thenvector comprises genetic information for antisense therapy, ornfor genes which will combat tumors, such as genes encodingncytokines, preferably IL-1, or so called suicide genes, suchnas Herpes Simplex Virus thymidine kinase. n Methods for producing said vectors and methods of genentherapy or uses therein are also disclosed. |
| priorityDate |
1994-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |